AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Core gross margin (% of product sales) by Year
Core gross margin (% of product sales) (%)
AstraZeneca Core gross margin (% of product sales): 82.0% in FY2025.
Latest, FY2025
82.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
4 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| - Gross Margin | 82% | 82% | - | -1pp”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Core Financial Measures.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core gross margin (% of product sales) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 82.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 80.0% | +5.8 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 74.2% | -5.8 pts | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 80.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Core gross margin (% of product sales) (%), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core-gross-margin-pct
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.
See a number that looks wrong?